Literature DB >> 6091710

The effect of etretinate on the cyclo-oxygenase and lipoxygenase products of arachidonic acid metabolism in psoriatic skin.

E Wong, R M Barr, S D Brain, M W Greaves, L A Olins, A I Mallet.   

Abstract

Eight psoriatic patients were treated with etretinate (50 mg daily) for 6 weeks. Skin chamber exudates from involved and uninvolved skin were assayed for arachidonic acid, 12-HETE, PGE2 and for neutrophil chemokinetic activity co-chromatographing with leukotriene B4, before and at weekly intervals during therapy. Pre-treatment concentrations of arachidonic acid, 12-HETE and leukotriene B4-like chemokinetic activity but not of PGE2 were elevated in involved skin when compared to uninvolved skin. The concentrations of arachidonic acid and 12-HETE declined during therapy but changes in PGE2 were minimal. LTB4-like activity was detectable in involved skin both before and after etretinate treatment. Clinically, scaling and infiltration improved but erythema was still evident.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6091710      PMCID: PMC1463606          DOI: 10.1111/j.1365-2125.1984.tb02499.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Psoriasis and leukotriene B4.

Authors:  S D Brain; R D Camp; P M Dowd; A K Black; P M Woollard; A I Mallet; M W Greaves
Journal:  Lancet       Date:  1982-10-02       Impact factor: 79.321

2.  Inhibition of neutrophil migration by etretinate and its main metabolite.

Authors:  L Dubertret; C Lebreton; R Touraine
Journal:  Br J Dermatol       Date:  1982-12       Impact factor: 9.302

3.  Arachidonic acid metabolism in polymorphonuclear leukocytes: effects of ionophore A23187.

Authors:  P Borgeat; B Samuelsson
Journal:  Proc Natl Acad Sci U S A       Date:  1979-05       Impact factor: 11.205

4.  Etretinate therapy for psoriasis: clinical responses, remission times, epidermal DNA and polyamine responses.

Authors:  R P Kaplan; D H Russell; N J Lowe
Journal:  J Am Acad Dermatol       Date:  1983-01       Impact factor: 11.527

5.  Stimulation of human eosinophil and neutrophil polymorphonuclear leukocyte chemotaxis and random migration by 12-L-hydroxy-5,8,10,14-eicosatetraenoic acid.

Authors:  E J Goetzl; J M Woods; R R Gorman
Journal:  J Clin Invest       Date:  1977-01       Impact factor: 14.808

6.  Increased concentrations of nonesterified arachidonic acid, 12L-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E2, and prostaglandin F2alpha in epidermis of psoriasis.

Authors:  S Hammarström; M Hamberg; B Samuelsson; E A Duell; M Stawiski; J J Voorhees
Journal:  Proc Natl Acad Sci U S A       Date:  1975-12       Impact factor: 11.205

7.  Increased concentrations of arachidonic acid, prostaglandins E2, D2, and 6-oxo-F1 alpha, and histamine in human skin following UVA irradiation.

Authors:  J L Hawk; A K Black; K F Jaenicke; R M Barr; N A Soter; A I Mallett; B A Gilchrest; C N Hensby; J A Parrish; M W Greaves
Journal:  J Invest Dermatol       Date:  1983-06       Impact factor: 8.551

8.  Responses of human skin to intradermal injection of leukotrienes C4, D4 and B4.

Authors:  R D Camp; A A Coutts; M W Greaves; A B Kay; M J Walport
Journal:  Br J Pharmacol       Date:  1983-11       Impact factor: 8.739

9.  The effects of some antirheumatic drugs on an in vitro model of human polymorphonuclear leucocyte chemokinesis.

Authors:  M J Smith; J R Walker
Journal:  Br J Pharmacol       Date:  1980-07       Impact factor: 8.739

10.  Systemic treatment of psoriasis with an oral retinoic acid derivative (Ro 10-9359).

Authors:  A Lassus
Journal:  Br J Dermatol       Date:  1980-02       Impact factor: 9.302

View more
  2 in total

1.  Topical steroid treatment reduces arachidonic acid and leukotriene B4 in lesional skin of psoriasis.

Authors:  E Wong; R M Barr; F M Cunningham; K Mistry; P M Woollard; A I Mallet; M W Greaves
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

2.  The in vitro 5-lipoxygenase and cyclo-oxygenase inhibitor L-652,343 does not inhibit 5-lipoxygenase in vivo in human skin.

Authors:  R M Barr; A K Black; P M Dowd; O Koro; K Mistry; J L Isaacs; M W Greaves
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.